Balance Sheet
Cash Flow Statement
Amortization of Deferred ChargesAsset Writedowns and ImpairmentCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in CashChange in InventoryChange in ReceivablesDepreciation & Amortization (CF)Depreciation and DepletionFree Cash FlowGains from Investment SecuritiesGains from Sales and DivestituresNet Cash FlowNet IncomeNon-cash ItemsOther Working Capital ChangesOther financing activitiesShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Aytu Biopharma (AYTU) Change in Receivables (2016 - 2025)

Historic Change in Receivables for Aytu Biopharma (AYTU) over the last 11 years, with Q4 2025 value amounting to -$2.3 million.

  • Aytu Biopharma's Change in Receivables fell 20132.04% to -$2.3 million in Q4 2025 from the same period last year, while for Dec 2025 it was $5.6 million, marking a year-over-year increase of 21266.84%. This contributed to the annual value of $7.6 million for FY2025, which is 24668.33% up from last year.
  • As of Q4 2025, Aytu Biopharma's Change in Receivables stood at -$2.3 million, which was down 20132.04% from $2.1 million recorded in Q3 2025.
  • Aytu Biopharma's Change in Receivables' 5-year high stood at $10.5 million during Q1 2025, with a 5-year trough of -$6.5 million in Q3 2021.
  • In the last 5 years, Aytu Biopharma's Change in Receivables had a median value of -$298000.0 in 2023 and averaged -$72000.0.
  • In the last 5 years, Aytu Biopharma's Change in Receivables crashed by 277545.45% in 2022 and then soared by 202542.37% in 2024.
  • Aytu Biopharma's Change in Receivables (Quarter) stood at $1.3 million in 2021, then tumbled by 277.6% to -$2.4 million in 2022, then soared by 95.04% to -$118000.0 in 2023, then skyrocketed by 2025.42% to $2.3 million in 2024, then tumbled by 201.32% to -$2.3 million in 2025.
  • Its Change in Receivables was -$2.3 million in Q4 2025, compared to $2.1 million in Q3 2025 and -$4.7 million in Q2 2025.